Theranostics Health Announces Peer-reviewed Publication Highlighting Utility of TheraLink® Assay

Theranostics Health Inc. announces today a joint publication with the Georgetown Lombardi Cancer Center in the American Cancer Society’s journal Cancer of “A Phase 1 Study of Cetuximab and Lapatinib in Patients with Advanced Solid Tumor Malignancies” that supports the use of measuring drug target up-regulation and activation to predict response to therapy.

Cancer Journal Deeken et al

Preeminent Oncology Researchers join the Medical Advisory Board of Theranostics Health

Theranostics Health welcomes the appointment of five preeminent medical researchers to its Medical Advisory Board (MAB).

  • Brian Leyland-Jones, MD serves as Vice President of Molecular and Experimental Medicine with Avera Medical Group.    Dr. Leyland-Jones will Chair the MAB.
  • Massimo Cristofanilli, MD serves as Director of the Jefferson Breast Care Center at the Kimmel Cancer Center and Thomas Jefferson University and Hospital.
  • Lance Liotta, MD, PhD serves as University Professor and Co-Director Center for Applied Proteomics and Molecular Medicine at George Mason University.
  • Joyce O’Shaughnessy, MD serves as Co-Chair of Breast Cancer Research at Baylor-Sammons Cancer Center and for the US Oncology Network.
  • Neil L. Spector, MD, serves as Associate Professor of Medicine, Pharmacology & Cancer Biology at the Duke University School of Medicine.

Theranostics Health_MAB PR_Feb 6, 2015

Theranostics Health Announces the Appointment of Luis Gutierrez as President and CEO

Theranostics Health, Inc., a biotechnology company that develops and commercializes molecular diagnostic technologies to target therapies for optimal patient benefit, announced today the appointment of Luis T. Gutierrez, Jr. as President and Chief Executive Officer.  In that role, he will also join the company’s Board of Directors.  Glenn D. Hoke, PhD will remain with the company in the role of Executive Vice President and Chief Operating Officer.

TH Luis Gutierrez Press Release 10.27.2014

 

Theranostics Health and Grace Bio-Labs Strike Licensing Agreement for Novel TheraLin® Tissue Fixative

Theranostics Health, Inc. and Grace Bio-Labs of have entered into a Product Licensing Agreement for the manufacture and market distribution of Theranostic’s novel tissue preservative, TheraLin®. Under the terms of the agreement, Grace Bio-Labs will be the commercial manufacturer and distributor for the patented (US Patent 8,460,859) TheraLin® fixative with the objective of accelerating the utilization of this novel reagent for advancement of cellular and protein analysis.

Theranostics_Grace_TheraLin Press Release

Select here for product and ordering information on the TheraLin® Tissue Fixative

 

 

Theranostics Health to Present at 8th Annual Mid-Atlantic BIO Conference

Gaithersburg, MD, August 17, 2012. Theranostics Health, Inc., a privately-held biotechnology company seeking to develop proteomic-based personalized medicine technologies, announced today that Dr. Glenn Hoke (President and Chief Executive Office) will be presenting at the Emerging Growth track at the 2012 Mid-Atlantic BIO Conference in Bethesda, MD. Dr. Hoke will be providing an overview to potential investors into Theranostics Health’s scientific and business development efforts to commercialize Theranostics’ TheraLink™ Assays for use in patients with malignant diseases.

Mid-Atlantic BIO Investor Presentations